Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Antimicrob Agents Chemother ; 67(4): e0125322, 2023 04 18.
Artigo em Inglês | MEDLINE | ID: mdl-36975834

RESUMO

Azole resistance in Aspergillus fumigatus is on the rise. Nontarget-mediated mechanisms are a common cause of azole resistance in chronic pulmonary aspergillosis (CPA). Here, we investigate resistance mechanisms using whole-genome sequencing. Sixteen azole-resistant A. fumigatus isolates from CPA were sequenced to assess genome rearrangements. Seven out of 16 CPA isolates showed genomic duplications compared to zero out of 18 invasive isolates. Duplication of regions, including cyp51A, increased gene expression. Our results suggest aneuploidy as an azole resistance mechanism in CPA.


Assuntos
Aspergilose , Aspergilose Pulmonar , Humanos , Aspergillus fumigatus/genética , Aspergillus fumigatus/metabolismo , Azóis/farmacologia , Aspergilose/tratamento farmacológico , Antifúngicos/farmacologia , Antifúngicos/uso terapêutico , Proteínas Fúngicas/genética , Proteínas Fúngicas/metabolismo , Farmacorresistência Fúngica/genética , Aspergilose Pulmonar/tratamento farmacológico , Aneuploidia , Testes de Sensibilidade Microbiana
2.
Intensive Care Med ; 43(9): 1225-1238, 2017 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-28255613

RESUMO

PURPOSE: To describe concisely the current standards of care, major recent advances, common beliefs that have been contradicted by recent trials, areas of uncertainty, and clinical studies that need to be performed over the next decade and their expected outcomes with regard to Candida and Aspergillus infections in non-neutropenic patients in the ICU setting. METHODS: A systematic review of the medical literature taking account of national and international guidelines and expert opinion. RESULTS: Severe invasive fungal infections (IFIs) are becoming increasingly frequent in critically ill patients. Approximately 80% of IFIs are due to Candida spp. and 0.3-19% to Aspergillus spp. Recent observations emphasize the necessity of building a worldwide sentinel network to monitor the emergence of new fungal species and changes in susceptibility. Robust data on the attributable mortality are essential for the design of clinical studies with mortality endpoints. Although early antifungal therapy for Candida has been recommended in patients with risk factors, sepsis of unknown cause, and positive Candida serum biomarkers [ß-1 â†’ 3-D-glucan (BDG) and Candida albicans germ tube antibody (CAGTA)], its usefulness and influence on outcome need to be confirmed. Future studies may specifically address the optimal diagnostic and therapeutic strategies for patients with abdominal candidiasis. Better knowledge of the pharmacokinetics of antifungal molecules and tissue penetration is a key issue for intensivists. Regarding invasive aspergillosis, further investigation is needed to determine its incidence in the ICU, its relationship with influenza outbreaks, the clinical impact of rapid diagnosis, and the significance of combination treatment. CONCLUSIONS: Fundamental questions regarding IFI have to be addressed over the next decade. The clinical studies described in this research agenda should provide a template and set priorities for the clinical investigations that need to be performed.


Assuntos
Antifúngicos/farmacologia , Candidemia , Aspergilose Pulmonar Invasiva , Padrão de Cuidado/normas , Anticorpos Antifúngicos/sangue , Antifúngicos/uso terapêutico , Aspergillus/imunologia , Aspergillus/isolamento & purificação , Biomarcadores/sangue , Pesquisa Biomédica , Candida/imunologia , Candida/isolamento & purificação , Candidemia/diagnóstico , Candidemia/tratamento farmacológico , Candidemia/mortalidade , Candidemia/prevenção & controle , Estado Terminal/mortalidade , Saúde Global , Humanos , Incidência , Unidades de Terapia Intensiva , Infecções Fúngicas Invasivas/diagnóstico por imagem , Infecções Fúngicas Invasivas/tratamento farmacológico , Infecções Fúngicas Invasivas/mortalidade , Infecções Fúngicas Invasivas/prevenção & controle , Aspergilose Pulmonar Invasiva/diagnóstico , Aspergilose Pulmonar Invasiva/tratamento farmacológico , Aspergilose Pulmonar Invasiva/mortalidade , Aspergilose Pulmonar Invasiva/prevenção & controle , Guias de Prática Clínica como Assunto , Ensaios Clínicos Controlados Aleatórios como Assunto , Fatores de Risco
3.
Protein Pept Lett ; 9(6): 533-43, 2002 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-12553862

RESUMO

Temporin A, 18 analogs, and a cecropin A-temporin A hybrid peptide were tested with antibiotic sensitive and resistant bacteria, fungi, human erythrocytes, and in clotting assays. Several peptides were active in these assays, and some analogs (D-TA, W1-TA, and Con-L4,G10) may be useful lead compounds for further antibiotics development. The activity of temporin A was found to be dependent upon several of its structural features, including amino acid composition and sequence, chirality, helicity, and positive charge.


Assuntos
Antibacterianos/farmacologia , Peptídeos Catiônicos Antimicrobianos/farmacologia , Proteínas/farmacologia , Proteínas Recombinantes de Fusão/farmacologia , Antibacterianos/química , Antifúngicos/química , Peptídeos Catiônicos Antimicrobianos/química , Bioensaio , Hemólise/efeitos dos fármacos , Humanos , Peptídeos/química , Proteínas/química , Proteínas Recombinantes de Fusão/química , Relação Estrutura-Atividade
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa